Literature DB >> 31040497

Bronchopulmonary Dysplasia: When the Very Preterm Baby Comes Home.

Connie Anderson1, Noah H Hillman1.   

Abstract

Many infants with severe bronchopulmonary dysplasia (BPD) can be safely managed with oxygen at home. This review covers criteria for home oxygen therapy, monitoring, and weaning protocols for oxygen therapy in the outpatient setting. Although most infants with BPD are weaned from oxygen within a year, they continue to have pulmonary function abnormalities into adolescence. These infants also require evaluation for pulmonary hypertension, systemic hypertension, and a strong focus on adequate nutritional needs for growth.

Entities:  

Mesh:

Year:  2019        PMID: 31040497      PMCID: PMC6461314     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  4 in total

1.  Characteristics of home oxygen therapy for preterm infants with bronchopulmonary dysplasia in China: results of a multicenter cohort study.

Authors:  Wen-Xing Jiang; Yan-Chen Wang; Hong-Xia Song; Mi Xiao; Fan He; Si-Yuan Jiang; Xin-Yue Gu; Jian-Hua Sun; Yun Cao; Wen-Hao Zhou; Shoo Kim Lee; Li-Ping Chen; Li-Yuan Hu
Journal:  World J Pediatr       Date:  2022-08-11       Impact factor: 9.186

2.  Predicting tracheal work of breathing in neonates based on radiological and pulmonary measurements.

Authors:  Chamindu C Gunatilaka; Erik B Hysinger; Andreas Schuh; Qiwei Xiao; Deep B Gandhi; Nara S Higano; Daniel Ignatiuk; Md M Hossain; Robert J Fleck; Jason C Woods; Alister J Bates
Journal:  J Appl Physiol (1985)       Date:  2022-09-01

3.  Using a home oxygen weaning protocol and pCO2 to evaluate outcomes for infants with bronchopulmonary dysplasia discharged on home oxygen.

Authors:  Sara K Dawson; Lynn A D'Andrea; Ryan Lau; Joanne M Lagatta
Journal:  Pediatr Pulmonol       Date:  2020-09-15

4.  Bone mesenchymal stem cell-derived exosomes prevent hyperoxia-induced apoptosis of primary type II alveolar epithelial cells in vitro.

Authors:  Wei Yang; Chao Huang; Wenjian Wang; Baozhu Zhang; Yunbin Chen; Xinlin Xie
Journal:  PeerJ       Date:  2022-09-02       Impact factor: 3.061

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.